AL'FAKAL'TsIDOL ILI KOLEKAL'TsIFEROL V KOMBINATsII S IBANDRONOVOY KISLOTOY PRI LEChENII POSTMENOPAUZAL'NOGO SISTEMNOGO OSTEOPOROZA

Alfacalcidol or colecalciferol in combination with ibandronic aciWhen a comparative study of the ibandronic acid (Bonviva) using with two forms of vitamin D (colecalciferol and alfacalcidol) was conducted, it has been showed that in some patients with initially a slight increase in the level of reso...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	S S RODIONOVA [verfasserIn] A A ELOVOY-VRONSKIY [verfasserIn] A I BERNAKEVICh [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch ; Russisch

Erschienen:	2014

Übergeordnetes Werk:	In: Остеопороз и остеопатии - Endocrinology Research Centre, 2018, 17(2014), 1, Seite 21-24
Übergeordnetes Werk:	volume:17 ; year:2014 ; number:1 ; pages:21-24

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc Journal toc

DOI / URN:	10.14341/osteo2014121-24

Katalog-ID:	DOAJ006006205

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ006006205
003	DE-627
005	20230309195238.0
007	cr uuu---uuuuu
008	230225s2014 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.14341/osteo2014121-24 \|2 doi
035			\|a (DE-627)DOAJ006006205
035			\|a (DE-599)DOAJe1b609950ff644d7ab3ca915d2920198
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng \|a rus
050		0	\|a RZ301-397.5
100	0		\|a S S RODIONOVA \|e verfasserin \|4 aut
245	1	0	\|a AL'FAKAL'TsIDOL ILI KOLEKAL'TsIFEROL V KOMBINATsII S IBANDRONOVOY KISLOTOY PRI LEChENII POSTMENOPAUZAL'NOGO SISTEMNOGO OSTEOPOROZA
264		1	\|c 2014
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Alfacalcidol or colecalciferol in combination with ibandronic aciWhen a comparative study of the ibandronic acid (Bonviva) using with two forms of vitamin D (colecalciferol and alfacalcidol) was conducted, it has been showed that in some patients with initially a slight increase in the level of resorption markers colecalciferol, in contradistinction to alfacalcidol, not always it is possible to prevent the development of hypocalcemia and secondary hyperparathyroidism. As well, the appointment of colecalciferol may lead to hypocalcemia as a hidden manifestation of excessive oppression remodeling influenced ibandronate in patients with the presence of somatic pathology with an impact on vitamin D metabolism. In the current study, the clinical confirmation of excessive oppression remodeling and failure D hormone was the smaller increase of BMD at lumbar, no significant increase in femoral neck fractures and a higher incidence in the group receiving colecalciferol compared to the group receiving alfacalcidol. Increasing of 25(OH)D concentrations in the blood of patients while taking colecalciferol doesn’t guarantees rising of D-hormone.
653		0	\|a Osteopathy
700	0		\|a A A ELOVOY-VRONSKIY \|e verfasserin \|4 aut
700	0		\|a A I BERNAKEVICh \|e verfasserin \|4 aut
773	0	8	\|i In \|t Остеопороз и остеопатии \|d Endocrinology Research Centre, 2018 \|g 17(2014), 1, Seite 21-24 \|w (DE-627)1760648779 \|x 23110716 \|7 nnns
773	1	8	\|g volume:17 \|g year:2014 \|g number:1 \|g pages:21-24
856	4	0	\|u https://doi.org/10.14341/osteo2014121-24 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/e1b609950ff644d7ab3ca915d2920198 \|z kostenfrei
856	4	0	\|u https://endojournals.ru/index.php/osteo/article/view/8873 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2072-2680 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2311-0716 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
951			\|a AR
952			\|d 17 \|j 2014 \|e 1 \|h 21-24

Indexfelder

author_variant	s s r ssr a a e v aaev a i b aib
matchkey_str	article:23110716:2014----::laatioiioeatieovobntisbnrnvyiltyrlceipsmnp
hierarchy_sort_str	2014
callnumber-subject-code	RZ
publishDate	2014
allfields	10.14341/osteo2014121-24 doi (DE-627)DOAJ006006205 (DE-599)DOAJe1b609950ff644d7ab3ca915d2920198 DE-627 ger DE-627 rakwb eng rus RZ301-397.5 S S RODIONOVA verfasserin aut AL'FAKAL'TsIDOL ILI KOLEKAL'TsIFEROL V KOMBINATsII S IBANDRONOVOY KISLOTOY PRI LEChENII POSTMENOPAUZAL'NOGO SISTEMNOGO OSTEOPOROZA 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Alfacalcidol or colecalciferol in combination with ibandronic aciWhen a comparative study of the ibandronic acid (Bonviva) using with two forms of vitamin D (colecalciferol and alfacalcidol) was conducted, it has been showed that in some patients with initially a slight increase in the level of resorption markers colecalciferol, in contradistinction to alfacalcidol, not always it is possible to prevent the development of hypocalcemia and secondary hyperparathyroidism. As well, the appointment of colecalciferol may lead to hypocalcemia as a hidden manifestation of excessive oppression remodeling influenced ibandronate in patients with the presence of somatic pathology with an impact on vitamin D metabolism. In the current study, the clinical confirmation of excessive oppression remodeling and failure D hormone was the smaller increase of BMD at lumbar, no significant increase in femoral neck fractures and a higher incidence in the group receiving colecalciferol compared to the group receiving alfacalcidol. Increasing of 25(OH)D concentrations in the blood of patients while taking colecalciferol doesn’t guarantees rising of D-hormone. Osteopathy A A ELOVOY-VRONSKIY verfasserin aut A I BERNAKEVICh verfasserin aut In Остеопороз и остеопатии Endocrinology Research Centre, 2018 17(2014), 1, Seite 21-24 (DE-627)1760648779 23110716 nnns volume:17 year:2014 number:1 pages:21-24 https://doi.org/10.14341/osteo2014121-24 kostenfrei https://doaj.org/article/e1b609950ff644d7ab3ca915d2920198 kostenfrei https://endojournals.ru/index.php/osteo/article/view/8873 kostenfrei https://doaj.org/toc/2072-2680 Journal toc kostenfrei https://doaj.org/toc/2311-0716 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 17 2014 1 21-24
spelling	10.14341/osteo2014121-24 doi (DE-627)DOAJ006006205 (DE-599)DOAJe1b609950ff644d7ab3ca915d2920198 DE-627 ger DE-627 rakwb eng rus RZ301-397.5 S S RODIONOVA verfasserin aut AL'FAKAL'TsIDOL ILI KOLEKAL'TsIFEROL V KOMBINATsII S IBANDRONOVOY KISLOTOY PRI LEChENII POSTMENOPAUZAL'NOGO SISTEMNOGO OSTEOPOROZA 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Alfacalcidol or colecalciferol in combination with ibandronic aciWhen a comparative study of the ibandronic acid (Bonviva) using with two forms of vitamin D (colecalciferol and alfacalcidol) was conducted, it has been showed that in some patients with initially a slight increase in the level of resorption markers colecalciferol, in contradistinction to alfacalcidol, not always it is possible to prevent the development of hypocalcemia and secondary hyperparathyroidism. As well, the appointment of colecalciferol may lead to hypocalcemia as a hidden manifestation of excessive oppression remodeling influenced ibandronate in patients with the presence of somatic pathology with an impact on vitamin D metabolism. In the current study, the clinical confirmation of excessive oppression remodeling and failure D hormone was the smaller increase of BMD at lumbar, no significant increase in femoral neck fractures and a higher incidence in the group receiving colecalciferol compared to the group receiving alfacalcidol. Increasing of 25(OH)D concentrations in the blood of patients while taking colecalciferol doesn’t guarantees rising of D-hormone. Osteopathy A A ELOVOY-VRONSKIY verfasserin aut A I BERNAKEVICh verfasserin aut In Остеопороз и остеопатии Endocrinology Research Centre, 2018 17(2014), 1, Seite 21-24 (DE-627)1760648779 23110716 nnns volume:17 year:2014 number:1 pages:21-24 https://doi.org/10.14341/osteo2014121-24 kostenfrei https://doaj.org/article/e1b609950ff644d7ab3ca915d2920198 kostenfrei https://endojournals.ru/index.php/osteo/article/view/8873 kostenfrei https://doaj.org/toc/2072-2680 Journal toc kostenfrei https://doaj.org/toc/2311-0716 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 17 2014 1 21-24
allfields_unstemmed	10.14341/osteo2014121-24 doi (DE-627)DOAJ006006205 (DE-599)DOAJe1b609950ff644d7ab3ca915d2920198 DE-627 ger DE-627 rakwb eng rus RZ301-397.5 S S RODIONOVA verfasserin aut AL'FAKAL'TsIDOL ILI KOLEKAL'TsIFEROL V KOMBINATsII S IBANDRONOVOY KISLOTOY PRI LEChENII POSTMENOPAUZAL'NOGO SISTEMNOGO OSTEOPOROZA 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Alfacalcidol or colecalciferol in combination with ibandronic aciWhen a comparative study of the ibandronic acid (Bonviva) using with two forms of vitamin D (colecalciferol and alfacalcidol) was conducted, it has been showed that in some patients with initially a slight increase in the level of resorption markers colecalciferol, in contradistinction to alfacalcidol, not always it is possible to prevent the development of hypocalcemia and secondary hyperparathyroidism. As well, the appointment of colecalciferol may lead to hypocalcemia as a hidden manifestation of excessive oppression remodeling influenced ibandronate in patients with the presence of somatic pathology with an impact on vitamin D metabolism. In the current study, the clinical confirmation of excessive oppression remodeling and failure D hormone was the smaller increase of BMD at lumbar, no significant increase in femoral neck fractures and a higher incidence in the group receiving colecalciferol compared to the group receiving alfacalcidol. Increasing of 25(OH)D concentrations in the blood of patients while taking colecalciferol doesn’t guarantees rising of D-hormone. Osteopathy A A ELOVOY-VRONSKIY verfasserin aut A I BERNAKEVICh verfasserin aut In Остеопороз и остеопатии Endocrinology Research Centre, 2018 17(2014), 1, Seite 21-24 (DE-627)1760648779 23110716 nnns volume:17 year:2014 number:1 pages:21-24 https://doi.org/10.14341/osteo2014121-24 kostenfrei https://doaj.org/article/e1b609950ff644d7ab3ca915d2920198 kostenfrei https://endojournals.ru/index.php/osteo/article/view/8873 kostenfrei https://doaj.org/toc/2072-2680 Journal toc kostenfrei https://doaj.org/toc/2311-0716 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 17 2014 1 21-24
allfieldsGer	10.14341/osteo2014121-24 doi (DE-627)DOAJ006006205 (DE-599)DOAJe1b609950ff644d7ab3ca915d2920198 DE-627 ger DE-627 rakwb eng rus RZ301-397.5 S S RODIONOVA verfasserin aut AL'FAKAL'TsIDOL ILI KOLEKAL'TsIFEROL V KOMBINATsII S IBANDRONOVOY KISLOTOY PRI LEChENII POSTMENOPAUZAL'NOGO SISTEMNOGO OSTEOPOROZA 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Alfacalcidol or colecalciferol in combination with ibandronic aciWhen a comparative study of the ibandronic acid (Bonviva) using with two forms of vitamin D (colecalciferol and alfacalcidol) was conducted, it has been showed that in some patients with initially a slight increase in the level of resorption markers colecalciferol, in contradistinction to alfacalcidol, not always it is possible to prevent the development of hypocalcemia and secondary hyperparathyroidism. As well, the appointment of colecalciferol may lead to hypocalcemia as a hidden manifestation of excessive oppression remodeling influenced ibandronate in patients with the presence of somatic pathology with an impact on vitamin D metabolism. In the current study, the clinical confirmation of excessive oppression remodeling and failure D hormone was the smaller increase of BMD at lumbar, no significant increase in femoral neck fractures and a higher incidence in the group receiving colecalciferol compared to the group receiving alfacalcidol. Increasing of 25(OH)D concentrations in the blood of patients while taking colecalciferol doesn’t guarantees rising of D-hormone. Osteopathy A A ELOVOY-VRONSKIY verfasserin aut A I BERNAKEVICh verfasserin aut In Остеопороз и остеопатии Endocrinology Research Centre, 2018 17(2014), 1, Seite 21-24 (DE-627)1760648779 23110716 nnns volume:17 year:2014 number:1 pages:21-24 https://doi.org/10.14341/osteo2014121-24 kostenfrei https://doaj.org/article/e1b609950ff644d7ab3ca915d2920198 kostenfrei https://endojournals.ru/index.php/osteo/article/view/8873 kostenfrei https://doaj.org/toc/2072-2680 Journal toc kostenfrei https://doaj.org/toc/2311-0716 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 17 2014 1 21-24
allfieldsSound	10.14341/osteo2014121-24 doi (DE-627)DOAJ006006205 (DE-599)DOAJe1b609950ff644d7ab3ca915d2920198 DE-627 ger DE-627 rakwb eng rus RZ301-397.5 S S RODIONOVA verfasserin aut AL'FAKAL'TsIDOL ILI KOLEKAL'TsIFEROL V KOMBINATsII S IBANDRONOVOY KISLOTOY PRI LEChENII POSTMENOPAUZAL'NOGO SISTEMNOGO OSTEOPOROZA 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Alfacalcidol or colecalciferol in combination with ibandronic aciWhen a comparative study of the ibandronic acid (Bonviva) using with two forms of vitamin D (colecalciferol and alfacalcidol) was conducted, it has been showed that in some patients with initially a slight increase in the level of resorption markers colecalciferol, in contradistinction to alfacalcidol, not always it is possible to prevent the development of hypocalcemia and secondary hyperparathyroidism. As well, the appointment of colecalciferol may lead to hypocalcemia as a hidden manifestation of excessive oppression remodeling influenced ibandronate in patients with the presence of somatic pathology with an impact on vitamin D metabolism. In the current study, the clinical confirmation of excessive oppression remodeling and failure D hormone was the smaller increase of BMD at lumbar, no significant increase in femoral neck fractures and a higher incidence in the group receiving colecalciferol compared to the group receiving alfacalcidol. Increasing of 25(OH)D concentrations in the blood of patients while taking colecalciferol doesn’t guarantees rising of D-hormone. Osteopathy A A ELOVOY-VRONSKIY verfasserin aut A I BERNAKEVICh verfasserin aut In Остеопороз и остеопатии Endocrinology Research Centre, 2018 17(2014), 1, Seite 21-24 (DE-627)1760648779 23110716 nnns volume:17 year:2014 number:1 pages:21-24 https://doi.org/10.14341/osteo2014121-24 kostenfrei https://doaj.org/article/e1b609950ff644d7ab3ca915d2920198 kostenfrei https://endojournals.ru/index.php/osteo/article/view/8873 kostenfrei https://doaj.org/toc/2072-2680 Journal toc kostenfrei https://doaj.org/toc/2311-0716 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 17 2014 1 21-24
language	English Russian
source	In Остеопороз и остеопатии 17(2014), 1, Seite 21-24 volume:17 year:2014 number:1 pages:21-24
sourceStr	In Остеопороз и остеопатии 17(2014), 1, Seite 21-24 volume:17 year:2014 number:1 pages:21-24
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Osteopathy
isfreeaccess_bool	true
container_title	Остеопороз и остеопатии
authorswithroles_txt_mv	S S RODIONOVA @@aut@@ A A ELOVOY-VRONSKIY @@aut@@ A I BERNAKEVICh @@aut@@
publishDateDaySort_date	2014-01-01T00:00:00Z
hierarchy_top_id	1760648779
id	DOAJ006006205
language_de	englisch russisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ006006205</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309195238.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2014 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.14341/osteo2014121-24</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ006006205</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJe1b609950ff644d7ab3ca915d2920198</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RZ301-397.5</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">S S RODIONOVA</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">AL'FAKAL'TsIDOL ILI KOLEKAL'TsIFEROL V KOMBINATsII S IBANDRONOVOY KISLOTOY PRI LEChENII POSTMENOPAUZAL'NOGO SISTEMNOGO OSTEOPOROZA</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Alfacalcidol or colecalciferol in combination with ibandronic aciWhen a comparative study of the ibandronic acid (Bonviva) using with two forms of vitamin D (colecalciferol and alfacalcidol) was conducted, it has been showed that in some patients with initially a slight increase in the level of resorption markers colecalciferol, in contradistinction to alfacalcidol, not always it is possible to prevent the development of hypocalcemia and secondary hyperparathyroidism. As well, the appointment of colecalciferol may lead to hypocalcemia as a hidden manifestation of excessive oppression remodeling influenced ibandronate in patients with the presence of somatic pathology with an impact on vitamin D metabolism. In the current study, the clinical confirmation of excessive oppression remodeling and failure D hormone was the smaller increase of BMD at lumbar, no significant increase in femoral neck fractures and a higher incidence in the group receiving colecalciferol compared to the group receiving alfacalcidol. Increasing of 25(OH)D concentrations in the blood of patients while taking colecalciferol doesn’t guarantees rising of D-hormone.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Osteopathy</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A A ELOVOY-VRONSKIY</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A I BERNAKEVICh</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Остеопороз и остеопатии</subfield><subfield code="d">Endocrinology Research Centre, 2018</subfield><subfield code="g">17(2014), 1, Seite 21-24</subfield><subfield code="w">(DE-627)1760648779</subfield><subfield code="x">23110716</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:17</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:21-24</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.14341/osteo2014121-24</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/e1b609950ff644d7ab3ca915d2920198</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://endojournals.ru/index.php/osteo/article/view/8873</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2072-2680</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2311-0716</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">17</subfield><subfield code="j">2014</subfield><subfield code="e">1</subfield><subfield code="h">21-24</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	S S RODIONOVA
spellingShingle	S S RODIONOVA misc RZ301-397.5 misc Osteopathy AL'FAKAL'TsIDOL ILI KOLEKAL'TsIFEROL V KOMBINATsII S IBANDRONOVOY KISLOTOY PRI LEChENII POSTMENOPAUZAL'NOGO SISTEMNOGO OSTEOPOROZA
authorStr	S S RODIONOVA
ppnlink_with_tag_str_mv	@@773@@(DE-627)1760648779
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RZ301-397
illustrated	Not Illustrated
issn	23110716
topic_title	RZ301-397.5 AL'FAKAL'TsIDOL ILI KOLEKAL'TsIFEROL V KOMBINATsII S IBANDRONOVOY KISLOTOY PRI LEChENII POSTMENOPAUZAL'NOGO SISTEMNOGO OSTEOPOROZA
topic	misc RZ301-397.5 misc Osteopathy
topic_unstemmed	misc RZ301-397.5 misc Osteopathy
topic_browse	misc RZ301-397.5 misc Osteopathy
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Остеопороз и остеопатии
hierarchy_parent_id	1760648779
hierarchy_top_title	Остеопороз и остеопатии
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)1760648779
title	AL'FAKAL'TsIDOL ILI KOLEKAL'TsIFEROL V KOMBINATsII S IBANDRONOVOY KISLOTOY PRI LEChENII POSTMENOPAUZAL'NOGO SISTEMNOGO OSTEOPOROZA
ctrlnum	(DE-627)DOAJ006006205 (DE-599)DOAJe1b609950ff644d7ab3ca915d2920198
title_full	AL'FAKAL'TsIDOL ILI KOLEKAL'TsIFEROL V KOMBINATsII S IBANDRONOVOY KISLOTOY PRI LEChENII POSTMENOPAUZAL'NOGO SISTEMNOGO OSTEOPOROZA
author_sort	S S RODIONOVA
journal	Остеопороз и остеопатии
journalStr	Остеопороз и остеопатии
callnumber-first-code	R
lang_code	eng rus
isOA_bool	true
recordtype	marc
publishDateSort	2014
contenttype_str_mv	txt
container_start_page	21
author_browse	S S RODIONOVA A A ELOVOY-VRONSKIY A I BERNAKEVICh
container_volume	17
class	RZ301-397.5
format_se	Elektronische Aufsätze
author-letter	S S RODIONOVA
doi_str_mv	10.14341/osteo2014121-24
author2-role	verfasserin
title_sort	al'fakal'tsidol ili kolekal'tsiferol v kombinatsii s ibandronovoy kislotoy pri lechenii postmenopauzal'nogo sistemnogo osteoporoza
callnumber	RZ301-397.5
title_auth	AL'FAKAL'TsIDOL ILI KOLEKAL'TsIFEROL V KOMBINATsII S IBANDRONOVOY KISLOTOY PRI LEChENII POSTMENOPAUZAL'NOGO SISTEMNOGO OSTEOPOROZA
abstract	Alfacalcidol or colecalciferol in combination with ibandronic aciWhen a comparative study of the ibandronic acid (Bonviva) using with two forms of vitamin D (colecalciferol and alfacalcidol) was conducted, it has been showed that in some patients with initially a slight increase in the level of resorption markers colecalciferol, in contradistinction to alfacalcidol, not always it is possible to prevent the development of hypocalcemia and secondary hyperparathyroidism. As well, the appointment of colecalciferol may lead to hypocalcemia as a hidden manifestation of excessive oppression remodeling influenced ibandronate in patients with the presence of somatic pathology with an impact on vitamin D metabolism. In the current study, the clinical confirmation of excessive oppression remodeling and failure D hormone was the smaller increase of BMD at lumbar, no significant increase in femoral neck fractures and a higher incidence in the group receiving colecalciferol compared to the group receiving alfacalcidol. Increasing of 25(OH)D concentrations in the blood of patients while taking colecalciferol doesn’t guarantees rising of D-hormone.
abstractGer	Alfacalcidol or colecalciferol in combination with ibandronic aciWhen a comparative study of the ibandronic acid (Bonviva) using with two forms of vitamin D (colecalciferol and alfacalcidol) was conducted, it has been showed that in some patients with initially a slight increase in the level of resorption markers colecalciferol, in contradistinction to alfacalcidol, not always it is possible to prevent the development of hypocalcemia and secondary hyperparathyroidism. As well, the appointment of colecalciferol may lead to hypocalcemia as a hidden manifestation of excessive oppression remodeling influenced ibandronate in patients with the presence of somatic pathology with an impact on vitamin D metabolism. In the current study, the clinical confirmation of excessive oppression remodeling and failure D hormone was the smaller increase of BMD at lumbar, no significant increase in femoral neck fractures and a higher incidence in the group receiving colecalciferol compared to the group receiving alfacalcidol. Increasing of 25(OH)D concentrations in the blood of patients while taking colecalciferol doesn’t guarantees rising of D-hormone.
abstract_unstemmed	Alfacalcidol or colecalciferol in combination with ibandronic aciWhen a comparative study of the ibandronic acid (Bonviva) using with two forms of vitamin D (colecalciferol and alfacalcidol) was conducted, it has been showed that in some patients with initially a slight increase in the level of resorption markers colecalciferol, in contradistinction to alfacalcidol, not always it is possible to prevent the development of hypocalcemia and secondary hyperparathyroidism. As well, the appointment of colecalciferol may lead to hypocalcemia as a hidden manifestation of excessive oppression remodeling influenced ibandronate in patients with the presence of somatic pathology with an impact on vitamin D metabolism. In the current study, the clinical confirmation of excessive oppression remodeling and failure D hormone was the smaller increase of BMD at lumbar, no significant increase in femoral neck fractures and a higher incidence in the group receiving colecalciferol compared to the group receiving alfacalcidol. Increasing of 25(OH)D concentrations in the blood of patients while taking colecalciferol doesn’t guarantees rising of D-hormone.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ
container_issue	1
title_short	AL'FAKAL'TsIDOL ILI KOLEKAL'TsIFEROL V KOMBINATsII S IBANDRONOVOY KISLOTOY PRI LEChENII POSTMENOPAUZAL'NOGO SISTEMNOGO OSTEOPOROZA
url	https://doi.org/10.14341/osteo2014121-24 https://doaj.org/article/e1b609950ff644d7ab3ca915d2920198 https://endojournals.ru/index.php/osteo/article/view/8873 https://doaj.org/toc/2072-2680 https://doaj.org/toc/2311-0716
remote_bool	true
author2	A A ELOVOY-VRONSKIY A I BERNAKEVICh
author2Str	A A ELOVOY-VRONSKIY A I BERNAKEVICh
ppnlink	1760648779
callnumber-subject	RZ - Other Systems of Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.14341/osteo2014121-24
callnumber-a	RZ301-397.5
up_date	2024-07-03T18:25:48.102Z
_version_	1803583381154299904
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ006006205</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309195238.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2014 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.14341/osteo2014121-24</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ006006205</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJe1b609950ff644d7ab3ca915d2920198</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RZ301-397.5</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">S S RODIONOVA</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">AL'FAKAL'TsIDOL ILI KOLEKAL'TsIFEROL V KOMBINATsII S IBANDRONOVOY KISLOTOY PRI LEChENII POSTMENOPAUZAL'NOGO SISTEMNOGO OSTEOPOROZA</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Alfacalcidol or colecalciferol in combination with ibandronic aciWhen a comparative study of the ibandronic acid (Bonviva) using with two forms of vitamin D (colecalciferol and alfacalcidol) was conducted, it has been showed that in some patients with initially a slight increase in the level of resorption markers colecalciferol, in contradistinction to alfacalcidol, not always it is possible to prevent the development of hypocalcemia and secondary hyperparathyroidism. As well, the appointment of colecalciferol may lead to hypocalcemia as a hidden manifestation of excessive oppression remodeling influenced ibandronate in patients with the presence of somatic pathology with an impact on vitamin D metabolism. In the current study, the clinical confirmation of excessive oppression remodeling and failure D hormone was the smaller increase of BMD at lumbar, no significant increase in femoral neck fractures and a higher incidence in the group receiving colecalciferol compared to the group receiving alfacalcidol. Increasing of 25(OH)D concentrations in the blood of patients while taking colecalciferol doesn’t guarantees rising of D-hormone.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Osteopathy</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A A ELOVOY-VRONSKIY</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A I BERNAKEVICh</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Остеопороз и остеопатии</subfield><subfield code="d">Endocrinology Research Centre, 2018</subfield><subfield code="g">17(2014), 1, Seite 21-24</subfield><subfield code="w">(DE-627)1760648779</subfield><subfield code="x">23110716</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:17</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:21-24</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.14341/osteo2014121-24</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/e1b609950ff644d7ab3ca915d2920198</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://endojournals.ru/index.php/osteo/article/view/8873</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2072-2680</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2311-0716</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">17</subfield><subfield code="j">2014</subfield><subfield code="e">1</subfield><subfield code="h">21-24</subfield></datafield></record></collection>
score	7.4014883

Nicht das Richtige dabei?

Schreiben Sie uns!

AL'FAKAL'TsIDOL ILI KOLEKAL'TsIFEROL V KOMBINATsII S IBANDRONOVOY KISLOTOY PRI LEChENII POSTMENOPAUZAL'NOGO SISTEMNOGO OSTEOPOROZA

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?